- Home
- ADPT vs ROOT Comparison
ADPT vs ROOT Comparison
Compare ADPT & ROOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- ROOT
- Stock Information
- Founded
- ADPT 2009
- ROOT 2015
- Country
- ADPT United States
- ROOT United States
- Employees
- ADPT N/A
- ROOT N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- ROOT Property-Casualty Insurers
- Sector
- ADPT Health Care
- ROOT Finance
- Exchange
- ADPT Nasdaq
- ROOT Nasdaq
- Market Cap
- ADPT 2.0B
- ROOT 2.3B
- IPO Year
- ADPT 2019
- ROOT 2020
- Fundamental
- Price
- ADPT $14.40
- ROOT $80.94
- Analyst Decision
- ADPT Strong Buy
- ROOT Buy
- Analyst Count
- ADPT 9
- ROOT 6
- Target Price
- ADPT $13.22
- ROOT $130.60
- AVG Volume (30 Days)
- ADPT 2.1M
- ROOT 488.8K
- Earning Date
- ADPT 11-06-2025
- ROOT 10-29-2025
- Dividend Yield
- ADPT N/A
- ROOT N/A
- EPS Growth
- ADPT N/A
- ROOT N/A
- EPS
- ADPT N/A
- ROOT 4.73
- Revenue
- ADPT $205,216,000.00
- ROOT $1,364,700,000.00
- Revenue This Year
- ADPT $32.76
- ROOT $27.41
- Revenue Next Year
- ADPT $15.81
- ROOT $9.74
- P/E Ratio
- ADPT N/A
- ROOT $17.31
- Revenue Growth
- ADPT 21.60
- ROOT 59.76
- 52 Week Low
- ADPT $4.27
- ROOT $36.87
- 52 Week High
- ADPT $15.26
- ROOT $181.14
- Technical
- Relative Strength Index (RSI)
- ADPT 60.53
- ROOT 33.20
- Support Level
- ADPT $14.04
- ROOT $89.55
- Resistance Level
- ADPT $15.26
- ROOT $92.27
- Average True Range (ATR)
- ADPT 0.73
- ROOT 4.42
- MACD
- ADPT 0.05
- ROOT -1.30
- Stochastic Oscillator
- ADPT 69.09
- ROOT 1.57
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.